Nyxoah (NASDAQ:NYXH) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Nyxoah (NASDAQ:NYXH) issued its quarterly earnings results on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04), FiscalAI reports. The business had revenue of $6.62 million during the quarter, compared to analyst estimates of $5.70 million. Nyxoah had a negative net margin of 1,457.97% and a negative return on equity of 101.99%.

Here are the key takeaways from Nyxoah’s conference call:

• The company received FDA approval for Genio in August 2025, secured Medicare and broad commercial reimbursement, and quickly generated U.S. revenue (about $4.5M in Q4) contributing to EUR 11M global gross revenue and ~EUR 10M net revenue for 2025 with ~63–64% gross margin.
• Commercial execution accelerated: 145 surgeons trained across ~125 targeted accounts, 120 Value Analysis Committee submissions with 57 approvals, and the U.S. sales force expanded from 25 to 40 reps now covering ~200 of the top 400 accounts.
• Clinical and regulatory catalysts are in progress — the DREAM pivotal study was published showing efficacy in supine and non‑supine positions, and 12‑month ACCCESS data are expected by end‑June 2026 to support a PMA supplement and potential U.S. label expansion in early 2027.
• Profitability and cash runway remain challenges: 2025 operating loss widened to EUR 83.5M, cash totaled EUR 48M at year‑end, management estimates ~EUR 20M quarterly cash burn and says current funding supports operations into Q1 2027 absent faster revenue ramp or additional financing.

Nyxoah Stock Up 1.0%

NASDAQ:NYXH traded up $0.03 on Thursday, hitting $3.09. The company had a trading volume of 19,062 shares, compared to its average volume of 59,705. The firm has a 50 day moving average of $4.41 and a two-hundred day moving average of $4.88. Nyxoah has a 52 week low of $3.05 and a 52 week high of $11.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.70 and a quick ratio of 1.41.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nyxoah in a research note on Monday, December 29th. Stifel Nicolaus reduced their target price on Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. Finally, Cantor Fitzgerald raised shares of Nyxoah to a “strong-buy” rating in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Hedge Funds Weigh In On Nyxoah

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. lifted its holdings in Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares during the period. Bank of America Corp DE raised its position in shares of Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after acquiring an additional 3,303 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Nyxoah in the third quarter worth approximately $98,000. Deutsche Bank AG increased its position in Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the period. Finally, Shay Capital LLC bought a new position in Nyxoah during the 2nd quarter worth approximately $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.